BOYNTON BEACH, Fla., Nov. 25, 2003 (PRIMEZONE) -- Dr. Jerry I. Jacobson, Chairman, Chief Executive Officer and Chief Science and Technology Officer of Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announces today the publication of a successful wound healing study in rats in The American Journal of Veterinary Research (July 2003). This study was conducted at Mississippi State University.
The objective of this study was to evaluate the effects of extremely low intensity and low frequency electromagnetic fields on healing of sutured and open skin wounds and clinico-pathologic variables in rats. An incision made in the back of the neck was sutured (32 rats) or left open to heal (32 rats). In each group 16 rats were not treated (controls). The other 16 rats in each group were treated daily with the proprietary signal protocols for the Jacobson Resonators. Rats were euthanatized at days 2,4,7 and 14. Wounds were evaluated via tensiometry (sutured), digital planimetry (open), laser Doppler perfusion imaging, bacteriologic culture, and histologic examination. Blood samples were collected.
At day 14, sutured wounds in treated rats were stronger (ultimate stress) and tougher (strain energy) than the controls. Open wounds in treated rats contracted more quickly at days 2 and 4 than the controls. Histologic changes indicative of improved healing, in sutured and open wounds treated with the Jacobson Resonator were detected as early as day 4.
"It is important to note that exposure to our signal parameters caused no adverse effects of clinico-pathologic, histologic or bacteriologic variables tested in the study. It appears that Jacobson Resonance is a safe form of adjuvant treatment for wounds, and improves strength of sutured wounds, while speeding contraction of open wounds. It is important to continue our rigorous scientific studies as we develop our technology, aiming towards the ultimate goal, the amelioration of human suffering," Dr. Jacobson stated.
Dr. Jacobson continued, "Additionally, application of various protocols may be evaluated in the Caribbean, with special interest also in sports medicine. If an important athlete can be healed faster, time on the disabled list will be cut shorter and thus more dollars earned, while yielding another path to increase shareholder value."
Harvey Grossman, President and Chief Strategic Officer states, "We plan on conducting further laboratory experiments in the wound healing area. We also foresee in the coming years conducting double blind clinical trials for FDA, European Union and Health Canada clearances and approvals in the wound healing area such as from abrasions, contusions, burns, ulcers, diabetic wounds, and more. Upon receiving clearances, new treatment markets will be open to our patented technology."
Illustration: According to a "Visiongain" in-depth analysis, the value in 2002 of the world market for wound care products was nearly 6 billion dollars and by 2008 it will climb to 7 billion dollars. Wound care products used to treat traumatic injury and surgical wounds alone, will garner revenues in excess of $4.3 billion, according to a 2003 study released by "Kalorama Information." And, finally the market for wound care products aimed at the care of skin ulcers topped $2.5 billion worldwide in 2002, according to a study released in 2003 from "Kalorama Information." Skin ulcers affect approximately 18 million people.
Upon FDA, EU, and Health Canada clearances and approvals, our goal is to penetrate 3% to 5% of the market segment for each indication within 10 years of clearance or approval.(1)
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
(1) Although we have set what we believe is a responsible goal there is no assurance that we will achieve this anticipated market penetration. We recognize that there is competition in this marketplace, and that to achieve our goal, we will need to establish significant revenue streams to avoid the need for additional funding, as well as FDA, EU and Health Canada clearances for certain applications of our resonator technology.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances. For further information, contact Anthony P. Fusco, Jr. at (561) 752.4141.